

Product supply shortage addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross has been advised by Sun Pharma Global FZE that the shortage of Sumatriptan Sun 12 mg/ml Injection Syringe (DIN 02361698) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **June 10, 2016**.

SUMATRIPTAN SUCCINATE

6 MG / SYR INJECTION SYRINGE

00002361698	SUMATRIPTAN SUN (0.5 ML)	SPG	\$33.1745
00002212188	IMITREX (0.5 ML)	GSK	\$45.4100

Removal of temporary benefit from the *Alberta Drug Benefit List (ADBL)*

Due to the shortage of Ciloxan 0.3% Ophthalmic Solution (DIN 01945270) manufactured by Alcon Canada Inc., Sandoz Ciprofloxacin 0.3% Ophthalmic Solution (DIN 02387131) manufactured by Sandoz Canada Inc. was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

Alcon Canada Inc. has advised Alberta Blue Cross that the shortage of Ciloxan 0.3% Ophthalmic Solution (DIN 01945270) has been resolved.

As a result, Sandoz Ciprofloxacin 0.3% Ophthalmic Solution (DIN 02387131) will no longer be considered a temporary benefit for the *ADBL* **after June 10, 2016**.

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • **403-294-4041** (Calgary and area) • **1-800-361-9632** (toll free)
FAX 780-498-8406 (Edmonton and area) • **FAX 1-877-305-9911** (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims. Visit <https://www.ab.bluecross.ca/providers/pharmacy-home.php>

